Articles On Pharmaxis (ASX:PXS)

On Stockhead today, what small fries can learn from big health caps, an expert’s view of where crypto is headed, and Barry FitzGerald gets his heavy metal on.   But first, here’s what you need to know. The day ahead Australian labour market...

The company is confident that the FDA will have the information it requires to be able to approve Bronchitol by Q1 2020.

Pharmaxis (ASX:PXS) chief Gary Phillips is keen to differentiate the drug developer from his local peers, noting the company has several potential paths to glory rather than a singular approach. “A lot of biotechs in Australia are a one-pro...

I have recently spent some time reviewing the annual reports and announcements from S&P/ASX 200 (INDEXASX: XJO) index-listed company, Starpharma Holdings Limited (ASX: SPL) to assess the merit of buying SPL shares. Starpharma shares la...

In this week's Weekly Insights (published in two parts):-Crucial Question: Is It 1995 or 2007?-Conviction Calls -Gold Stocks: Winners & Losers-Rudi On Tour -Rudi TalksConviction Calls By Rudi Filapek-Vandyck, Editor FNArena Stockb...

Avita Medical Ltd Strong Performance During the Third Quarter of 2019: Avita Medical Ltd (ASX: AVH) released its quarterly report for the period ended 31 March 2019 on 30 April 2019. The company mentioned that for the third quarter of 2019,...

If Bronchitol is approved by the US FDA, Pharmaxis will receive US$10 million.